Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Anthony Elias

Concepts (631)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
108
2024
2133
6.380
 Why?
Antineoplastic Combined Chemotherapy Protocols
95
2024
1560
3.820
 Why?
Sarcoma
32
2022
176
3.190
 Why?
Receptors, Estrogen
22
2021
422
2.380
 Why?
Triple Negative Breast Neoplasms
14
2024
193
2.330
 Why?
Receptor, ErbB-2
22
2024
326
2.100
 Why?
Hematopoietic Stem Cell Transplantation
36
2011
576
2.070
 Why?
Carcinoma, Small Cell
19
2003
169
1.750
 Why?
Soft Tissue Neoplasms
14
2022
111
1.620
 Why?
Carcinoma, Ductal, Breast
7
2018
80
1.520
 Why?
Neoadjuvant Therapy
17
2024
379
1.380
 Why?
Antineoplastic Agents
31
2023
2046
1.290
 Why?
Neoplasm Recurrence, Local
20
2022
958
1.240
 Why?
Neoplasm Staging
35
2024
1282
1.100
 Why?
Lung Neoplasms
38
2003
2342
1.070
 Why?
Receptors, Progesterone
13
2020
341
1.070
 Why?
Combined Modality Therapy
52
2024
1203
1.040
 Why?
Biomarkers, Tumor
17
2022
1164
1.020
 Why?
Paclitaxel
14
2024
217
0.940
 Why?
Mastectomy
9
2018
132
0.930
 Why?
Bone Marrow Transplantation
27
1998
277
0.930
 Why?
Bone Neoplasms
7
2025
229
0.870
 Why?
Doxorubicin
23
2024
329
0.830
 Why?
Antineoplastic Agents, Alkylating
5
2018
67
0.770
 Why?
Female
167
2025
68734
0.750
 Why?
Receptors, Androgen
7
2018
143
0.740
 Why?
Disease-Free Survival
24
2023
646
0.730
 Why?
Antibodies, Monoclonal, Humanized
9
2024
757
0.710
 Why?
Humans
222
2025
129626
0.700
 Why?
Antineoplastic Agents, Hormonal
10
2018
155
0.690
 Why?
Maytansine
3
2021
16
0.670
 Why?
Liposarcoma
4
2023
27
0.670
 Why?
Middle Aged
110
2025
31136
0.670
 Why?
Neoplasm Metastasis
23
2024
611
0.620
 Why?
Chemotherapy, Adjuvant
23
2023
377
0.600
 Why?
Dioxoles
2
2015
9
0.580
 Why?
Tetrahydroisoquinolines
2
2015
8
0.580
 Why?
Cyclophosphamide
31
2024
234
0.580
 Why?
Adult
111
2025
35599
0.570
 Why?
Ifosfamide
19
1998
34
0.530
 Why?
Androgen Receptor Antagonists
6
2021
34
0.530
 Why?
Phenylthiohydantoin
5
2017
41
0.520
 Why?
Dasatinib
1
2016
54
0.520
 Why?
Trastuzumab
10
2024
100
0.510
 Why?
Neoplasms, Hormone-Dependent
3
2012
38
0.490
 Why?
Treatment Outcome
43
2024
10219
0.490
 Why?
Aged
63
2025
22061
0.490
 Why?
Estrogen Receptor alpha
5
2021
130
0.460
 Why?
Drug Administration Schedule
24
2018
767
0.460
 Why?
Carboplatin
21
2016
139
0.460
 Why?
Granulocyte Colony-Stimulating Factor
11
2002
73
0.450
 Why?
Carcinoma, Non-Small-Cell Lung
17
2001
1049
0.440
 Why?
Clinical Trials as Topic
19
2018
1005
0.430
 Why?
Estrogens
6
2018
347
0.420
 Why?
Dacarbazine
9
2018
93
0.400
 Why?
Neoplasms
20
2009
2455
0.390
 Why?
Survival Rate
19
2021
1872
0.380
 Why?
Tamoxifen
9
2018
197
0.370
 Why?
Survival Analysis
23
2010
1269
0.370
 Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2013
949
0.360
 Why?
Pyrimidines
3
2020
459
0.350
 Why?
Antibodies, Monoclonal
9
2024
1366
0.350
 Why?
Neoplasms, Second Primary
3
2022
106
0.340
 Why?
Carcinoma, Intraductal, Noninfiltrating
3
2022
55
0.340
 Why?
Prognosis
21
2021
3774
0.340
 Why?
Dose-Response Relationship, Drug
17
2017
2011
0.340
 Why?
Granulocyte-Macrophage Colony-Stimulating Factor
8
1999
147
0.340
 Why?
Taxoids
7
2023
98
0.330
 Why?
Remission Induction
16
2002
274
0.330
 Why?
Breast Neoplasms, Male
3
2018
29
0.320
 Why?
Drug Resistance, Neoplasm
7
2017
752
0.320
 Why?
Gene Expression Regulation, Neoplastic
11
2018
1336
0.300
 Why?
Neoplastic Cells, Circulating
2
2020
70
0.300
 Why?
Mesna
12
1998
15
0.290
 Why?
Sarcoma, Ewing
3
2022
87
0.280
 Why?
Leiomyosarcoma
2
2018
27
0.270
 Why?
Cisplatin
14
2000
299
0.270
 Why?
Immunoconjugates
3
2024
104
0.260
 Why?
Sternum
1
2006
25
0.260
 Why?
Tumor Microenvironment
4
2024
627
0.260
 Why?
Immunohistochemistry
5
2016
1685
0.260
 Why?
Mastectomy, Segmental
2
2009
86
0.250
 Why?
Pyridines
2
2025
478
0.250
 Why?
Chondrosarcoma
1
2025
15
0.240
 Why?
Peripheral Blood Stem Cell Transplantation
2
2002
21
0.240
 Why?
Carcinoma, Ductal
1
2005
11
0.240
 Why?
Transplantation, Autologous
19
2002
213
0.240
 Why?
Melphalan
10
2002
29
0.240
 Why?
Isocitrate Dehydrogenase
1
2025
52
0.230
 Why?
Protein Kinase Inhibitors
4
2019
887
0.230
 Why?
Cell Adhesion Molecules
2
2021
173
0.230
 Why?
Lymph Nodes
1
2007
472
0.230
 Why?
Carcinoma
2
2008
214
0.230
 Why?
Glycine
1
2025
165
0.220
 Why?
Risk Reduction Behavior
2
2016
209
0.220
 Why?
Ovarian Neoplasms
3
2022
484
0.220
 Why?
Drug Evaluation
19
1998
82
0.220
 Why?
Adjuvants, Immunologic
3
2022
221
0.220
 Why?
Deoxycytidine
4
2020
164
0.220
 Why?
Survivors
3
2016
460
0.220
 Why?
Ribonuclease III
2
2016
37
0.210
 Why?
Hodgkin Disease
4
2016
134
0.210
 Why?
Thiotepa
13
2002
20
0.210
 Why?
Alkylating Agents
3
2000
24
0.210
 Why?
Behavior Therapy
2
2016
241
0.210
 Why?
Weight Loss
4
2016
738
0.210
 Why?
DEAD-box RNA Helicases
2
2016
66
0.210
 Why?
Male
65
2025
63670
0.210
 Why?
Triazoles
2
2022
148
0.200
 Why?
Gene Expression Profiling
6
2017
1687
0.200
 Why?
Medical Oncology
5
2024
269
0.200
 Why?
Disease Management
5
2020
588
0.200
 Why?
Employment
1
2024
167
0.200
 Why?
Obesity
4
2018
2882
0.200
 Why?
Mutation
4
2025
3717
0.200
 Why?
Overweight
3
2016
531
0.200
 Why?
Aged, 80 and over
13
2021
7052
0.190
 Why?
Salvage Therapy
6
2010
136
0.190
 Why?
Circulating Tumor DNA
1
2022
28
0.190
 Why?
Hydrazines
1
2022
34
0.190
 Why?
Referral and Consultation
1
2007
730
0.190
 Why?
Carcinoma in Situ
2
2012
45
0.190
 Why?
Etoposide
10
2001
148
0.190
 Why?
Emergency Medicine
1
2024
216
0.190
 Why?
Tumor Cells, Cultured
9
2020
943
0.180
 Why?
Hematologic Diseases
6
2008
62
0.180
 Why?
Sarcoma, Synovial
1
2021
17
0.180
 Why?
Liposarcoma, Myxoid
1
2021
9
0.180
 Why?
Aromatase Inhibitors
4
2021
51
0.180
 Why?
Recombinant Fusion Proteins
1
2024
651
0.180
 Why?
Endpoint Determination
1
2021
76
0.180
 Why?
Sentinel Lymph Node Biopsy
3
2017
108
0.170
 Why?
Time Factors
12
2020
6555
0.170
 Why?
Cancer Care Facilities
1
2020
32
0.170
 Why?
Hematopoietic Stem Cells
5
1996
382
0.170
 Why?
Indazoles
1
2020
66
0.170
 Why?
Leukocytes, Mononuclear
3
2020
546
0.170
 Why?
Cell Separation
3
2017
317
0.170
 Why?
Diphosphonates
1
2020
58
0.170
 Why?
Pyrroles
2
2013
202
0.160
 Why?
Diet
3
2018
1213
0.160
 Why?
Bone Marrow
8
2000
273
0.160
 Why?
Cell Line, Tumor
9
2017
3186
0.160
 Why?
Antigens, Neoplasm
4
2021
308
0.160
 Why?
Proportional Hazards Models
6
2020
1198
0.160
 Why?
MCF-7 Cells
5
2017
114
0.150
 Why?
Fluorouracil
7
2013
197
0.150
 Why?
CA-125 Antigen
2
2013
14
0.150
 Why?
Epithelial-Mesenchymal Transition
1
2020
201
0.150
 Why?
Benzamides
5
2017
203
0.150
 Why?
Nitriles
5
2017
170
0.150
 Why?
Bayes Theorem
4
2024
375
0.150
 Why?
Research Design
3
2021
1045
0.150
 Why?
Receptor, Fibroblast Growth Factor, Type 1
1
2018
51
0.150
 Why?
Programmed Cell Death 1 Receptor
1
2020
232
0.150
 Why?
Cyclin-Dependent Kinase 4
1
2018
45
0.140
 Why?
Cell Cycle
1
2021
588
0.140
 Why?
Indoles
2
2013
383
0.140
 Why?
Cyclin-Dependent Kinase 6
1
2018
40
0.140
 Why?
Infusions, Intravenous
10
2020
399
0.140
 Why?
Kaplan-Meier Estimate
6
2018
851
0.140
 Why?
Fibromatosis, Aggressive
1
2017
17
0.140
 Why?
Tetrahydronaphthalenes
1
2017
30
0.140
 Why?
Microbubbles
1
2017
48
0.140
 Why?
Vaccines
1
2022
400
0.140
 Why?
Valine
1
2017
81
0.140
 Why?
Internship and Residency
2
2024
1050
0.140
 Why?
Camptothecin
3
2024
110
0.140
 Why?
Lymph Node Excision
3
2015
164
0.130
 Why?
Immunotherapy
2
2018
596
0.130
 Why?
Amyloid Precursor Protein Secretases
1
2017
79
0.130
 Why?
Sulfonamides
1
2020
497
0.130
 Why?
Axilla
3
2017
45
0.130
 Why?
Androgen Antagonists
2
2015
79
0.130
 Why?
Cancer-Associated Fibroblasts
1
2016
13
0.130
 Why?
Gonadal Steroid Hormones
1
2018
132
0.130
 Why?
Neoplasms, Radiation-Induced
1
2016
71
0.130
 Why?
Neoplasms, Germ Cell and Embryonal
2
1995
70
0.130
 Why?
Hematopoietic Cell Growth Factors
2
1995
4
0.130
 Why?
Follow-Up Studies
6
2025
4894
0.130
 Why?
Ultrasonography, Mammary
1
2016
12
0.130
 Why?
Lymphatic Metastasis
3
2017
320
0.130
 Why?
Thiazoles
1
2016
117
0.130
 Why?
Antibody Specificity
1
2016
184
0.130
 Why?
Tumor Suppressor Protein p53
2
2023
507
0.130
 Why?
Neoplasm Invasiveness
3
2016
481
0.120
 Why?
Maximum Tolerated Dose
1
2016
193
0.120
 Why?
Antibiotics, Antineoplastic
1
2016
123
0.120
 Why?
Neoplastic Stem Cells
2
2017
378
0.120
 Why?
Quinolines
1
2016
156
0.120
 Why?
Benzimidazoles
1
2016
162
0.120
 Why?
Pyrazoles
1
2018
404
0.120
 Why?
Recurrence
5
2020
1011
0.120
 Why?
Mammography
1
2016
146
0.110
 Why?
Disease Progression
7
2018
2627
0.110
 Why?
Drug Therapy, Combination
4
2014
1042
0.110
 Why?
Radiotherapy, Adjuvant
5
2016
208
0.110
 Why?
Homeodomain Proteins
2
2018
494
0.110
 Why?
Administration, Oral
4
2020
787
0.110
 Why?
Young Adult
10
2025
12455
0.110
 Why?
TOR Serine-Threonine Kinases
1
2017
398
0.110
 Why?
Societies, Medical
1
2018
744
0.110
 Why?
Antibodies
1
2016
398
0.110
 Why?
Exercise
2
2015
1928
0.110
 Why?
Brain Edema
1
2014
60
0.110
 Why?
Radiotherapy Dosage
3
1999
251
0.110
 Why?
Hepatic Veno-Occlusive Disease
3
2002
14
0.110
 Why?
Animals
16
2021
35391
0.110
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
3
2022
90
0.110
 Why?
Comorbidity
5
2017
1547
0.110
 Why?
Vascular Neoplasms
1
2013
17
0.110
 Why?
Radiotherapy
3
2015
185
0.110
 Why?
Testicular Neoplasms
1
1995
102
0.110
 Why?
Clinical Trials, Phase I as Topic
3
2024
51
0.110
 Why?
Mice
12
2021
16961
0.110
 Why?
Epigenesis, Genetic
2
2018
617
0.110
 Why?
Adenocarcinoma
6
2015
893
0.100
 Why?
Cellular Reprogramming
1
2014
95
0.100
 Why?
Keratins
2
2017
175
0.100
 Why?
Bridged-Ring Compounds
3
2020
13
0.100
 Why?
Mercaptoethanol
2
1990
11
0.100
 Why?
Patient Selection
4
2016
661
0.100
 Why?
Apoptosis
6
2023
2492
0.100
 Why?
Cell Proliferation
6
2017
2373
0.100
 Why?
Gallium Radioisotopes
1
1992
14
0.100
 Why?
Bone Marrow Cells
4
2000
302
0.100
 Why?
Chromatin
1
2016
479
0.100
 Why?
Adolescent
23
2025
20412
0.100
 Why?
Carmustine
10
2001
50
0.100
 Why?
Protein-Tyrosine Kinases
2
2022
431
0.100
 Why?
Lymphoma, Non-Hodgkin
3
2001
78
0.100
 Why?
Retrospective Studies
12
2023
14522
0.100
 Why?
Anthracyclines
3
2023
49
0.100
 Why?
Brain Neoplasms
5
2014
1145
0.100
 Why?
Methotrexate
4
2002
249
0.090
 Why?
Weight Reduction Programs
1
2012
110
0.090
 Why?
Liver Neoplasms
3
2015
639
0.090
 Why?
Neoplasm, Residual
2
2022
121
0.090
 Why?
Radiosurgery
1
2014
321
0.090
 Why?
RNA, Catalytic
1
2012
185
0.090
 Why?
Aorta
1
2013
408
0.090
 Why?
Polydeoxyribonucleotides
2
2002
13
0.090
 Why?
Neutropenia
5
2013
137
0.090
 Why?
Neoplasm Grading
3
2017
282
0.090
 Why?
Carcinoma, Lobular
1
2011
47
0.090
 Why?
Leukapheresis
4
2001
21
0.090
 Why?
Multivariate Analysis
4
2013
1499
0.090
 Why?
Angiogenesis Inhibitors
1
2012
219
0.080
 Why?
Keratin-5
1
2010
50
0.080
 Why?
Biopsy
3
2018
1088
0.080
 Why?
Molecular Targeted Therapy
3
2018
391
0.080
 Why?
Electrophoresis, Gel, Two-Dimensional
1
2010
110
0.080
 Why?
Peptide Mapping
1
2010
63
0.080
 Why?
Databases, Protein
1
2010
61
0.080
 Why?
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
1
2010
136
0.080
 Why?
Urinary Tract
1
1990
38
0.080
 Why?
Postmenopause
2
2017
349
0.080
 Why?
Benzenesulfonates
1
2009
19
0.080
 Why?
CD146 Antigen
2
2021
41
0.080
 Why?
BRCA2 Protein
1
2009
54
0.080
 Why?
Health Facilities
1
2009
80
0.080
 Why?
Pregnancy Complications, Neoplastic
1
2009
53
0.080
 Why?
Observer Variation
1
2010
314
0.080
 Why?
Thrombophilia
1
2009
81
0.080
 Why?
Patient Care
1
2009
108
0.080
 Why?
United States
9
2023
13871
0.080
 Why?
Perimenopause
1
2008
60
0.070
 Why?
Fibrinolytic Agents
2
2002
262
0.070
 Why?
Mice, Nude
3
2017
682
0.070
 Why?
Randomized Controlled Trials as Topic
6
2000
1365
0.070
 Why?
Xenograft Model Antitumor Assays
3
2017
808
0.070
 Why?
Fatigue
3
2018
318
0.070
 Why?
In Situ Hybridization
2
2010
297
0.070
 Why?
Bone Marrow Diseases
4
2000
19
0.070
 Why?
In Situ Hybridization, Fluorescence
1
2008
313
0.070
 Why?
Blotting, Western
1
2010
1206
0.070
 Why?
Risk Assessment
2
2020
3262
0.070
 Why?
Reproducibility of Results
2
2016
3080
0.070
 Why?
Pneumonectomy
3
1997
151
0.070
 Why?
Sputum
1
1988
302
0.070
 Why?
Quality of Life
2
2015
2688
0.070
 Why?
Clinical Decision-Making
2
2020
301
0.060
 Why?
Risk Factors
7
2020
9786
0.060
 Why?
Neoplasm Proteins
2
2007
419
0.060
 Why?
Life Tables
2
2002
18
0.060
 Why?
Anilides
2
2016
70
0.060
 Why?
Positron-Emission Tomography
1
2006
282
0.060
 Why?
New Jersey
1
2024
12
0.060
 Why?
Predictive Value of Tests
2
2016
1947
0.060
 Why?
Colony-Stimulating Factors
3
1988
35
0.060
 Why?
Enzyme Inhibitors
1
2008
827
0.060
 Why?
Granulocytes
4
1995
77
0.060
 Why?
Receptor, TIE-2
1
2024
12
0.060
 Why?
Genes, Neoplasm
1
2004
20
0.060
 Why?
New York
1
2024
128
0.060
 Why?
Ricin
2
1997
8
0.060
 Why?
Growth Substances
3
1988
150
0.060
 Why?
Oligonucleotide Array Sequence Analysis
3
2012
756
0.060
 Why?
Magnetic Resonance Imaging
1
2016
3394
0.060
 Why?
Patient Care Planning
1
2005
146
0.050
 Why?
MicroRNAs
1
2010
679
0.050
 Why?
Forecasting
3
2000
361
0.050
 Why?
Thrombocytopenia
3
2013
186
0.050
 Why?
Mammaplasty
2
2016
101
0.050
 Why?
Signal Transduction
5
2018
4931
0.050
 Why?
Up-Regulation
2
2017
840
0.050
 Why?
Activating Transcription Factor 4
1
2023
20
0.050
 Why?
Proteasome Inhibitors
1
2023
42
0.050
 Why?
Proteomics
1
2010
1055
0.050
 Why?
Proto-Oncogene Proteins c-mdm2
1
2023
64
0.050
 Why?
Transcriptome
2
2023
876
0.050
 Why?
Cyclin E
1
2022
23
0.050
 Why?
G(M2) Ganglioside
1
2022
1
0.050
 Why?
Injection Site Reaction
1
2022
3
0.050
 Why?
Clinical Trials, Phase III as Topic
2
2000
93
0.050
 Why?
Treatment Failure
2
2001
339
0.050
 Why?
Proteasome Endopeptidase Complex
1
2023
149
0.050
 Why?
Oncogene Proteins
1
2022
55
0.050
 Why?
Luminescent Measurements
1
2003
76
0.050
 Why?
Ribose
1
2022
22
0.050
 Why?
Blood Transfusion, Autologous
2
1993
16
0.050
 Why?
Carbolines
1
2022
30
0.050
 Why?
Heterocyclic Compounds, 4 or More Rings
1
2022
19
0.050
 Why?
Career Choice
1
2024
207
0.050
 Why?
Adenosine Diphosphate
1
2022
80
0.050
 Why?
Class I Phosphatidylinositol 3-Kinases
1
2022
81
0.050
 Why?
Tomography, X-Ray Computed
2
2015
2512
0.050
 Why?
Oncogenes
1
2022
110
0.050
 Why?
Actuarial Analysis
2
1993
26
0.050
 Why?
Colony-Forming Units Assay
4
1996
90
0.050
 Why?
Cell Division
2
2001
796
0.050
 Why?
Gene Expression
2
2020
1465
0.050
 Why?
Carcinoembryonic Antigen
1
2001
39
0.040
 Why?
Fellowships and Scholarships
1
2024
276
0.040
 Why?
Phthalazines
1
2021
41
0.040
 Why?
Prospective Studies
5
2022
7135
0.040
 Why?
Age Factors
3
2018
3152
0.040
 Why?
Longitudinal Studies
2
2012
2720
0.040
 Why?
Clodronic Acid
1
2020
12
0.040
 Why?
Transplantation Immunology
1
2000
34
0.040
 Why?
Estradiol
2
2016
494
0.040
 Why?
Extracellular Matrix
1
2024
506
0.040
 Why?
Progesterone
1
2002
245
0.040
 Why?
Ligands
1
2022
621
0.040
 Why?
Phosphatidylinositol 3-Kinases
1
2022
361
0.040
 Why?
Topoisomerase I Inhibitors
1
1999
16
0.040
 Why?
Thoracotomy
2
1997
74
0.040
 Why?
Polymerase Chain Reaction
1
2003
1035
0.040
 Why?
Leucovorin
2
1997
70
0.040
 Why?
Bone Density Conservation Agents
1
2020
70
0.040
 Why?
Hematopoietic Stem Cell Mobilization
1
1999
22
0.040
 Why?
Dendritic Cells
2
2000
481
0.040
 Why?
Mechlorethamine
1
2000
63
0.040
 Why?
Myelodysplastic Syndromes
1
2001
129
0.040
 Why?
Drug Resistance
1
1999
165
0.040
 Why?
Neoplasms, Experimental
1
2000
170
0.040
 Why?
Child
8
2022
20884
0.040
 Why?
Heterocyclic Compounds, 3-Ring
1
2019
31
0.040
 Why?
Cell Cycle Proteins
1
2022
584
0.040
 Why?
Receptors, Steroid
1
2019
49
0.040
 Why?
Cluster Analysis
2
2012
482
0.040
 Why?
Piperazines
1
2021
340
0.040
 Why?
Etanidazole
1
1998
1
0.040
 Why?
Leukemia
1
2001
229
0.040
 Why?
Loss of Function Mutation
1
2018
39
0.040
 Why?
Enterocolitis, Pseudomembranous
1
1998
27
0.040
 Why?
Expectorants
1
1998
24
0.040
 Why?
Cross-Over Studies
1
2020
520
0.040
 Why?
Aurora Kinase A
1
2018
54
0.040
 Why?
Nervous System
2
1997
67
0.040
 Why?
Statistics, Nonparametric
1
1999
419
0.040
 Why?
Retreatment
1
2018
70
0.040
 Why?
Mediastinum
1
1998
24
0.040
 Why?
Disease Susceptibility
1
2020
334
0.040
 Why?
Nausea
1
2018
111
0.040
 Why?
Epithelial Cell Adhesion Molecule
1
2017
10
0.040
 Why?
Administration, Intravenous
1
2018
141
0.040
 Why?
Extremities
2
1989
127
0.040
 Why?
Watchful Waiting
1
2018
67
0.040
 Why?
SEER Program
1
2018
202
0.040
 Why?
Medicare
1
2023
708
0.040
 Why?
Breast
1
2018
153
0.030
 Why?
Double-Blind Method
1
2022
1875
0.030
 Why?
Diarrhea
1
2018
182
0.030
 Why?
Cell Hypoxia
1
1998
234
0.030
 Why?
Thorax
1
1997
41
0.030
 Why?
Random Allocation
2
1988
347
0.030
 Why?
Everolimus
1
2017
88
0.030
 Why?
Cohort Studies
4
2001
5426
0.030
 Why?
Phosphoramide Mustards
1
2016
2
0.030
 Why?
Heterografts
1
2017
133
0.030
 Why?
Immunotoxins
1
1997
54
0.030
 Why?
Cyclohexanes
1
2016
21
0.030
 Why?
Proto-Oncogene Proteins c-akt
1
2019
432
0.030
 Why?
Cell Survival
1
2000
1076
0.030
 Why?
Cytochrome P-450 CYP3A
1
2017
88
0.030
 Why?
Lymphoma, Large B-Cell, Diffuse
1
1998
114
0.030
 Why?
Placebos
1
2016
201
0.030
 Why?
Gene Knockdown Techniques
1
2017
317
0.030
 Why?
Carcinogenesis
1
2018
213
0.030
 Why?
Injections, Intravenous
2
1993
202
0.030
 Why?
Antineoplastic Agents, Immunological
1
2018
181
0.030
 Why?
Fertility Preservation
1
2016
39
0.030
 Why?
Blood Specimen Collection
1
1995
35
0.030
 Why?
Organoplatinum Compounds
3
1990
41
0.030
 Why?
Antidotes
1
1997
136
0.030
 Why?
Mortality
1
1997
307
0.030
 Why?
Blood Component Transfusion
2
1994
83
0.030
 Why?
Genetic Therapy
1
1997
289
0.030
 Why?
Digestive System
1
1995
29
0.030
 Why?
Transcriptional Activation
1
2017
367
0.030
 Why?
Vincristine
1
1995
108
0.030
 Why?
Kidney
2
1995
1386
0.030
 Why?
Fertility
1
2016
156
0.030
 Why?
Interleukin-3
1
1994
23
0.030
 Why?
Hormones
1
2015
141
0.030
 Why?
Weight Gain
1
2018
509
0.030
 Why?
Child, Preschool
6
2013
10490
0.030
 Why?
Pulmonary Fibrosis
3
1993
385
0.030
 Why?
Bacterial Infections
1
1996
235
0.030
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2017
253
0.030
 Why?
Adipose Tissue
1
2018
591
0.030
 Why?
Odds Ratio
1
2017
1019
0.030
 Why?
Leukocyte Count
5
1996
326
0.030
 Why?
Tosyl Compounds
1
2014
15
0.030
 Why?
Drug Discovery
1
2015
130
0.030
 Why?
Hand-Foot Syndrome
1
2013
2
0.030
 Why?
Protein Transport
1
2015
429
0.030
 Why?
Capecitabine
1
2013
45
0.030
 Why?
HEK293 Cells
1
2016
698
0.030
 Why?
Transplantation, Heterologous
1
2014
192
0.030
 Why?
Necrosis
1
2014
232
0.030
 Why?
Alternative Splicing
1
2015
217
0.030
 Why?
Neoplasm Transplantation
1
2014
256
0.030
 Why?
Cell Nucleus
1
2016
584
0.030
 Why?
Cross-Sectional Studies
1
2024
5075
0.030
 Why?
Erythropoietin
1
1994
88
0.030
 Why?
Binding Sites
1
2016
1248
0.030
 Why?
Gene Silencing
1
2014
190
0.030
 Why?
Blood Cells
1
1993
39
0.030
 Why?
Nutritional Status
1
2015
329
0.030
 Why?
Sensitivity and Specificity
2
2000
1843
0.030
 Why?
Recombinant Proteins
5
1997
1308
0.020
 Why?
Anemia
1
1994
161
0.020
 Why?
CD24 Antigen
1
2012
20
0.020
 Why?
Radionuclide Imaging
1
1992
122
0.020
 Why?
Energy Intake
1
2015
462
0.020
 Why?
Diet, Reducing
1
2012
87
0.020
 Why?
Psychotherapy, Group
1
2012
65
0.020
 Why?
Models, Biological
1
1999
1724
0.020
 Why?
Hyaluronan Receptors
1
2012
97
0.020
 Why?
Antigens, CD34
3
1996
88
0.020
 Why?
Counseling
1
2015
386
0.020
 Why?
Surveys and Questionnaires
1
2024
5415
0.020
 Why?
Feasibility Studies
4
1998
869
0.020
 Why?
Mice, SCID
1
2012
350
0.020
 Why?
Vascular Endothelial Growth Factor Receptor-1
1
2012
71
0.020
 Why?
Tumor Burden
1
2012
286
0.020
 Why?
Fluorescent Antibody Technique
2
1990
376
0.020
 Why?
Logistic Models
1
2016
1986
0.020
 Why?
Disease Models, Animal
1
2021
4078
0.020
 Why?
Biopsy, Needle
1
2011
188
0.020
 Why?
Mice, Inbred NOD
1
2012
587
0.020
 Why?
Colorado
1
2020
4404
0.020
 Why?
Chromosomes, Human, Pair 9
1
1990
39
0.020
 Why?
Blast Crisis
1
1990
33
0.020
 Why?
Chromosomes, Human, Pair 22
1
1990
40
0.020
 Why?
Bilirubin
2
2002
96
0.020
 Why?
Health Status
1
2015
756
0.020
 Why?
Immunoblotting
1
2010
305
0.020
 Why?
Pemetrexed
1
2010
32
0.020
 Why?
Gene Regulatory Networks
1
2012
281
0.020
 Why?
Glutamates
1
2010
57
0.020
 Why?
Kidney Diseases
2
1991
383
0.020
 Why?
Graft Survival
1
1993
513
0.020
 Why?
Cytokines
1
1998
2021
0.020
 Why?
Magnetics
1
1990
43
0.020
 Why?
Antibodies, Anti-Idiotypic
1
1990
58
0.020
 Why?
Guanine
1
2010
76
0.020
 Why?
Multiple Organ Failure
2
2002
123
0.020
 Why?
Urologic Diseases
1
1990
38
0.020
 Why?
Real-Time Polymerase Chain Reaction
1
2010
329
0.020
 Why?
Health Behavior
1
2015
743
0.020
 Why?
Microspheres
1
1990
124
0.020
 Why?
Chromosome Aberrations
1
1990
147
0.020
 Why?
Spinal Cord Neoplasms
1
1989
36
0.020
 Why?
Promoter Regions, Genetic
1
2014
1207
0.020
 Why?
Blood
1
1990
105
0.020
 Why?
Cell Movement
1
2014
948
0.020
 Why?
Clone Cells
1
1990
262
0.020
 Why?
Pregnancy Trimester, Second
1
2009
77
0.020
 Why?
Lymphoma
1
1990
199
0.020
 Why?
Hypertension
1
2018
1243
0.020
 Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
1990
118
0.020
 Why?
Central Nervous System Diseases
1
1990
69
0.020
 Why?
Hematuria
1
1989
12
0.020
 Why?
Vinblastine
2
2001
70
0.020
 Why?
DNA Methylation
1
2014
611
0.020
 Why?
False Negative Reactions
1
1988
53
0.020
 Why?
Creatinine
1
1991
490
0.020
 Why?
Pregnancy Trimester, First
1
2009
137
0.020
 Why?
Histones
1
2014
589
0.020
 Why?
Niacinamide
1
2009
75
0.020
 Why?
Leukopenia
1
1988
28
0.020
 Why?
Immunophenotyping
2
2000
311
0.020
 Why?
Phenylurea Compounds
1
2009
88
0.020
 Why?
Apoptosis Regulatory Proteins
1
2009
182
0.020
 Why?
Exercise Therapy
1
2012
412
0.020
 Why?
False Positive Reactions
1
1988
115
0.020
 Why?
Hospitals, Veterans
1
2009
243
0.020
 Why?
Electrophoresis
1
1988
30
0.020
 Why?
Macrophages
2
1995
1488
0.020
 Why?
Antigens, Differentiation
1
1988
82
0.020
 Why?
Transfection
1
2010
915
0.020
 Why?
Drug Interactions
1
1990
395
0.020
 Why?
Perilipin-1
1
2008
17
0.020
 Why?
Estrogen Receptor Modulators
1
2008
17
0.020
 Why?
Staining and Labeling
1
1988
142
0.020
 Why?
S100 Proteins
1
2008
36
0.020
 Why?
Antigens, Surface
1
1988
152
0.020
 Why?
Nervous System Diseases
1
1991
251
0.020
 Why?
Vimentin
1
1988
50
0.020
 Why?
Community Health Services
1
2009
228
0.020
 Why?
Androstadienes
1
2008
106
0.020
 Why?
Central Nervous System
1
1990
255
0.020
 Why?
Genetic Predisposition to Disease
1
2016
2274
0.020
 Why?
Sarcoma, Kaposi
1
1988
76
0.020
 Why?
Lung Diseases
2
1992
741
0.020
 Why?
Bone Marrow Purging
2
1996
3
0.020
 Why?
Health Knowledge, Attitudes, Practice
1
2015
1280
0.020
 Why?
Academic Medical Centers
1
2009
475
0.020
 Why?
Clinical Trials, Phase II as Topic
2
2000
72
0.020
 Why?
Biomarkers
1
2018
3968
0.020
 Why?
Risk
2
2000
855
0.020
 Why?
Heart Diseases
1
1990
352
0.020
 Why?
Gastrointestinal Diseases
1
2008
198
0.020
 Why?
Stem Cell Transplantation
1
2007
164
0.020
 Why?
Phosphoproteins
1
2008
335
0.020
 Why?
Immunoglobulin G
1
1990
851
0.020
 Why?
Bevacizumab
1
2006
128
0.020
 Why?
Quality of Health Care
1
2009
604
0.010
 Why?
Body Mass Index
1
2012
2274
0.010
 Why?
Melanoma
2
1988
730
0.010
 Why?
Carrier Proteins
1
2008
745
0.010
 Why?
Ascites
1
2002
44
0.010
 Why?
Cells, Cultured
1
1990
4084
0.010
 Why?
Brain
1
2014
2673
0.010
 Why?
Phenotype
1
2010
3075
0.010
 Why?
Carcinoma, Lewis Lung
1
2001
13
0.010
 Why?
Carcinoma, Large Cell
1
2001
15
0.010
 Why?
Transplantation Conditioning
1
2002
166
0.010
 Why?
Hemorrhage
2
1998
680
0.010
 Why?
Phytohemagglutinins
1
2000
29
0.010
 Why?
CD4-CD8 Ratio
1
2000
22
0.010
 Why?
Hypersensitivity, Delayed
1
2000
28
0.010
 Why?
Lymphocyte Culture Test, Mixed
1
2000
50
0.010
 Why?
Drug Synergism
1
2001
370
0.010
 Why?
Microcomputers
1
2000
16
0.010
 Why?
Graft vs Host Disease
1
2002
240
0.010
 Why?
Skin Tests
1
2000
100
0.010
 Why?
France
1
2000
29
0.010
 Why?
Louisiana
1
2000
27
0.010
 Why?
Philadelphia
1
2000
47
0.010
 Why?
Automation
1
2000
81
0.010
 Why?
Immunoglobulins
1
2000
161
0.010
 Why?
Immunity
1
2000
138
0.010
 Why?
Personnel Selection
1
1980
70
0.010
 Why?
Lung
1
1992
3938
0.010
 Why?
Marriage
1
1980
114
0.010
 Why?
Lipopolysaccharide Receptors
1
1999
86
0.010
 Why?
Heart Failure
1
1992
2133
0.010
 Why?
Thalassemia
1
1998
6
0.010
 Why?
Interleukin-4
1
1999
212
0.010
 Why?
Multicenter Studies as Topic
1
2000
286
0.010
 Why?
Receptors, Purinergic P1
1
1998
26
0.010
 Why?
Pilot Projects
2
1994
1592
0.010
 Why?
Microscopy, Fluorescence
1
2000
399
0.010
 Why?
Reference Values
1
2000
794
0.010
 Why?
Infant, Newborn
1
2009
5756
0.010
 Why?
Acute Disease
1
2001
979
0.010
 Why?
Filgrastim
1
1997
7
0.010
 Why?
Killer Cells, Natural
1
2000
426
0.010
 Why?
Adenoviruses, Human
1
1996
27
0.010
 Why?
Pregnancy
1
2009
6417
0.010
 Why?
Heparin
1
1998
254
0.010
 Why?
Lymphoma, B-Cell
1
1998
105
0.010
 Why?
Tissue Plasminogen Activator
1
1998
222
0.010
 Why?
Freezing
1
1996
87
0.010
 Why?
Lymphocyte Activation
1
2000
1109
0.010
 Why?
Lymphocyte Depletion
1
1996
134
0.010
 Why?
Genes, Reporter
1
1996
265
0.010
 Why?
Carcinoma, Squamous Cell
1
2001
627
0.010
 Why?
Drug Tolerance
1
1995
90
0.010
 Why?
Reticulocyte Count
1
1994
6
0.010
 Why?
Kidney Function Tests
1
1995
152
0.010
 Why?
Topotecan
1
1994
12
0.010
 Why?
Incidence
1
2001
2641
0.010
 Why?
Antigens, CD
1
1996
487
0.010
 Why?
Registries
1
2002
1899
0.010
 Why?
Liver
1
2002
1842
0.010
 Why?
Urinary Bladder Diseases
1
1993
18
0.010
 Why?
Glioblastoma
1
1996
322
0.010
 Why?
Heart
1
1997
641
0.010
 Why?
Flow Cytometry
1
1996
1159
0.010
 Why?
Boston
1
1993
89
0.010
 Why?
Chromatography, High Pressure Liquid
1
1995
580
0.010
 Why?
Iron
1
1994
282
0.010
 Why?
Palliative Care
1
1998
702
0.010
 Why?
Cell Line
1
1996
2784
0.010
 Why?
Immunologic Factors
1
1993
230
0.010
 Why?
Cystitis
1
1990
22
0.010
 Why?
Introns
1
1990
251
0.000
 Why?
Metabolic Clearance Rate
1
1989
117
0.000
 Why?
Prostatic Neoplasms
1
1996
998
0.000
 Why?
Platinum
1
1989
44
0.000
 Why?
Drug Combinations
1
1990
331
0.000
 Why?
Brain Diseases
1
1990
136
0.000
 Why?
Macrophage-1 Antigen
1
1988
28
0.000
 Why?
Bone Marrow Examination
1
1988
6
0.000
 Why?
Infant
1
2002
8995
0.000
 Why?
Platelet Count
1
1988
82
0.000
 Why?
Erythrocyte Count
1
1988
19
0.000
 Why?
Methods
1
1988
64
0.000
 Why?
Pelvic Neoplasms
1
1988
19
0.000
 Why?
Erythroblasts
1
1988
15
0.000
 Why?
DNA Damage
1
1990
384
0.000
 Why?
Acute Kidney Injury
1
1995
791
0.000
 Why?
Fever
1
1988
299
0.000
 Why?
Pneumonia
1
1992
617
0.000
 Why?
In Vitro Techniques
1
1988
1087
0.000
 Why?
Statistics as Topic
1
1987
305
0.000
 Why?
Elias's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (631) concept(s)
_
Co-Authors Expand Description
See all (60) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)